- Alembic Pharmaceuticals Limited marks entry into the US branded drug market with successful commercial rollout
- Pivya® (pivmecillinam) positioned as a first-line oral antibiotic for uncomplicated urinary tract infections in women
- Launch executed through Alembic Therapeutics LLC with targeted physician outreach across key US territories
- Strategic move strengthens Alembic’s specialty pharma ambitions in the world’s largest drug market
NE HEALTH BUREAU
MUMBAI, MAR 8
Alembic Pharmaceuticals Limited on Friday announced the first prescription-based sale of Pivya® (pivmecillinam) tablets, an oral prescription antibiotic, following its recent commercial launch in the United States.
Pivya® is Alembic’s first branded pharmaceutical product in the US and is being marketed through Alembic Therapeutics LLC, a step-down wholly owned subsidiary of the company.
The drug represents a first-line oral antibiotic option for the treatment of uncomplicated urinary tract infections (uUTIs) in women, a segment that has witnessed limited new product introductions for more than a decade, creating room for clinically established therapies with strong safety and efficacy profiles.
Commenting on the milestone, Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited, said: “The commercial launch of Pivya® marks an important milestone for Alembic as we enter the US branded pharmaceuticals market. What began as a strategic acquisition has now translated into a commercial presence in the specialty prescription segment. Pivya® represents the first step in Alembic’s strategy to build a focused branded specialty portfolio in the US, enabling us to participate in a large and stable therapeutic category with a clinically established and differentiated product. Over time, we intend to leverage this platform to build a broader branded portfolio in the US market.”
Market Context
Uncomplicated urinary tract infections remain among the most common bacterial infections in women in the US, leading to a significant number of outpatient antibiotic prescriptions each year.
With growing emphasis on appropriate antibiotic stewardship and the need for effective first-line therapies, clinically established agents such as pivmecillinam are expected to play an increasingly important role in managing uncomplicated urinary tract infections.
The therapeutic category represents a large and stable market accounting for nearly 30 million prescriptions annually in the US.
About Pivya® (pivmecillinam)
Pivya® contains pivmecillinam, a beta-lactam antibacterial agent with a long history of international clinical use. The medication belongs to the penicillin class of antibacterial drugs.
Pivya® is indicated for female patients aged 18 years and above for the treatment of uncomplicated urinary tract infections (uUTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Pivya® and other antibacterial drugs, the medication should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
Commercial Strategy
Alembic has established an initial sales footprint across key territories in the US, focusing on high-prescribing physicians in women’s health and engaging a targeted base of prescribers.
The company plans a phased expansion of its field force as prescription momentum builds, supported by targeted physician education and market access initiatives.
Strategic Context
Alembic continues to strengthen its presence in the US, one of the world’s largest pharmaceutical markets, through a balanced portfolio strategy spanning generics, specialty medicines and branded pharmaceuticals.
The launch of Pivya® marks an important step in building a focused branded business platform in the US, complementing the company’s established generics franchise.
The company reiterated its commitment to disciplined investments aimed at supporting sustainable growth and long-term value creation.
